The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease

Journal of Neuroscience Research

Volumn 89, Issue 1, 2011, Pages 22-28

  Jeynes, Brian ^a   Provias, John ^b  

^a BROCK UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Blood brain barrier

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOPROTEIN P; LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; TAU PROTEIN; VASCULOTROPIN;

ALZHEIMER DISEASE; AMNESIA; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; EFFUSION; GENE MUTATION; HOMEOSTASIS; HUMAN; MEMBRANE DAMAGE; MEMBRANE TRANSPORT; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN TRANSPORT; REVIEW; SENILE PLAQUE; TIGHT JUNCTION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; HUMANS;

EID: 78649518938     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22527     Document Type: Review

References (71)

1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. 2010. Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
2. Aliyev A, Seyidova D, Rzayev N, Obrenovich ME, Lamb BT, Chen SG, Smith MA, Perry G, de la Torre JC, Aliev G. 2004. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res 26: 547-553.
3. Alzheimer Society of Canada. 2010. Report. Rising tide: the impact of dementia on Canadian society. Toronto: Alzheimer Society of Canada
4. American Alzheimer's Association. 2010. Alzheimer's disease facts and figures. Alzheimer's Dement 6: 1-194.
5. Amor S, Puentes F, Baker Dvan der Valk P. 2010. Inflammation in neurodegenerative diseases. Immunology 129: 154-169.
6. Bell RD, Zlokovic BV. 2009. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-113.
7. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. 1995. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64: 749-760.
8. Bird TD. 2010. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene reviews [internet]. Seattle (WA): University of Washington, Seattle; 23 Oct 1993-1998 [updated 30 Mar 2010].
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. 2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112: 389-404.
10. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115: 3285-3290.
11. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43: 333-344.
12. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB. 2008. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118: 4002-4013.
13. Deane R, Bell RD, Sagare A, Zlokovic BV. 2009. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Targets 8: 16-30.
14. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR. 2010. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77: 82-102.
15. Donahue JE, Johanson CE. 2008. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease [review]. J Neuropathol Exp Neurol 67: 261-270; erratum in 67:634.
16. Donahue JE, Flaherty SL, Johanson CE, Duincan JA, Silverberg GD, Miller MC3rd, Tavares R, Yang W, Wu Q, Sabo E, et al. 2006. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112: 405-415.
17. Dvorak HF. 2006 Discovery of vascular permeability factor (VPF). Exp Cell Res 312: 522-526.
18. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ. 2010. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging doi: 10.1016/j.neurobiolaging.2010.03.011.
19. Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C. 1997. Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res Brain Res Rev 25: 217-245.
20. Gong CX, Grundke-Iqbal I, Iqbal K. 2010. Targeting tau protein in Alzheimer's disease. Drugs Aging 27: 351-365.
21. Greenberg DA, Jin K. 2005. From angiogenesis to neuropathology. Nature 438: 954-959.
22. Grignon Y, Duyckaerts C, Bennecib M, Hauw JJ. 1998. Cytoarchitectonic alterations in the supramarginal gyrus of late-onset Alzheimer's disease. Acta Neuropathol 95: 395-406.
23. Grosgen S, Grimm MO, Friess P, Hartman T. 2010. Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta 1801: 966-974.
24. Guglielmotto M, Giliberto L, Tamagno E, Tabaton M. 2010. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci 2: 3 doi: 10.3389/neuro.24.003.2010.
25. Guillozet AL, Weintraub S, Mash D, Mesulam MM. 2003. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60: 729-736.
26. Guix FX, Uribesalgo I, Coma M, Munoz FJ. 2005. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76: 126-152.
27. Hardy J. 2009. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110: 1129-1134.
28. Harris-White ME, Balverde Z, Lim GP, Kim P. 2004. Role of LRP in TGF2-mediated neuronal uptake of Abeta and effects on memory. J Neurosci Res 77: 217-228.
29. Hibbard LS, McKeel DWJr. 1997. Automated identification and quantitative morphometry of the senile plaques of Alzheimer's disease. Anal Quant Cytol Histol 19: 123-138.
30. Itzhaki RF, Wozniak MA. 2010. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 6: 83-84.
31. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-Demotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA. 2009. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-β protein, and impairs cognition. J Alzheimers Dis 17: 553-570.
32. Jeynes B, Provias 2006. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathol 112: 417-427.
33. Jeynes B, Provias J. 2008. Evidence for altered LRP/RAGE in Alzheimer lesion pathogenesis. Curr Alzheimers Res 5: 432-437.
34. Jeynes B, Provias J. 2009. Correlations between capillary expressed NOS isoforms presence and AD lesions in Alzheimer and normative brains. Neurosci Lett 463: 244-248.
35. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron 58: 681-693.
36. Keshet B, Yang IH, Good TA. 2010. Can size alone explain some of the differences in toxicity between beta-amyloid oligomers and fibrils. Biotechnol Bioeng 106: 333-337.
37. Korczyn AD. 2008. The amyloid cascade hypothesis. Alzheimers Dement 4: 176-178.
38. Krizanac-Bengez L, Kapural M, Parkinson F, Cucullo L, Hossain M, Mayberg MR, Janigro D. 2003. Effects of transient loss of shear stress on blood-brain barrier endothelium: role of nitric oxide and IL-6. Brain Res 977: 239-246.
39. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. 2001. Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 76: 1121-1128.
40. Lillis AP, Mikhailenko I, Strickland DK. 2005. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost 3: 1884-1893.
41. Lue LF, Yan SD, Stern DM, Walker DG. 2005. Preventing activation of receptor for advanced glycation end products in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 4: 249-266.
42. McCann SM, Mastronardi C, deLaurentiis A, Rettiri VA. 2005. The nitric oxide theory of aging revisited. Ann N Y Acad Sci 1057: 64-84.
43. McCarthy JV, Twomey C, Wujek P. 2009. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 66: 1534-1555.
44. Michalke B, Halbach S, Nischwitz V. 2009. JEM spotlight: metal speciation related to neurotoxicity in humans. J Environ Monit 11: 939-954.
45. Miller DS, Bauer B, Hartz AMS. 2008. Modulation of p-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209.
46. Moosy J, Zubenko GS, Martinez AJ, Rao GR. 1988. Bilateral symmetry of morphologic lesions in Alzheimer's disease. Arch Neurol 45: 251-254.
47. Mura E, Lanni C, Preda S, Pistoia F, Sara M, Racchi M, Schettini G, Marchi M, Govoni S. 2010. Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? Curr Pharm Des 16: 672-683.
48. Nazer B, Hong S, Selkoe DJ. 2008. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood-brain barrier in vitro model. Neurobiol Dis 30: 94-102.
49. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. 2007. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66: 1136-1146.
50. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. 2004. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24: 4259-4265.
51. Pimplikar SW. 2009. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41: 1261-1268.
52. Provias J, Jeynes B. 2008. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase. Curr Neurovasc Res 5: 199-205.
53. Rodrigue KM, Kennedy KM, Park DC. 2009. Beta-amyloid deposition and the aging brain [review]. Neuropsychol Rev 19: 436-450.
54. Savioz A, Leuba G, Vallet PG, Walzer C. 2009. Contribution of neural networks to Alzheimer disease's progression. Brain Res Bull 80: 309-314.
55. Senut MC, Roudier M, Davous P, Fallet-Bianco C, Lamour Y. 1991. Senile dementia of the Alzheimer type: is there a correlation between entorhinal cortex and dentate gyrus lesions? Acta Neuropathol 82: 306-315.
56. Shen S, Zhang W. 2010. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 21: 29-53.
57. Shin J, Lee S-Y, Kim S-H, Kim Y-B, Cho S-J. 2008. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 43: 236-244.
58. Small SA, Duff K. 2008. Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60: 534-542.
59. Sorrentino G, Bonavita V. 2007. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol Sci 28: 63-71.
60. Stefani M, Liguri G. 2009. Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimers Res 6: 15-29.
61. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Tredici KD, Attems J, Ghebremedhin, E. 2010. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol 120: 169-183.
62. Tomiyama T. 2010. The involvement of beta-amyloid in the etiology of Alzheimer disease. Brain Nerve 62: 691-699.
63. Ueno M, Nakagawa T, Wu B, Onodera M, Huang CL, Kusaka T, Araki N, Sakamoto H. 2010. Transporters in the brain endothelial barrier. Curr Med Chem 17: 1125-1138.
64. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU. 2008. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid β-protein in perivascular astrocytes. J Neuropathol Exp Neurol 67: 842-856.
65. Wang Y-J, Zhou H-D, Zhou X-F. 2006. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11: 931-938.
66. Weiss N, Miller F, Cazaubon S, Couraud P-O. 2009. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788: 842-857.
67. Weller RO, Boche D, Nicoll JAR. 2009. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 118: 87-102.
68. Yilmazer-Hanke DM, Hanke J. 1999. Progression of Alzheimer-related neuritic plaque pathology in the enthorinal region, perihinal cortex and hippocampal formation. Dement Geriatr Cogn Disord 10: 70-76.
69. Zetterberg H, Blennow K, Hanse E. 2010. Amyloid β and APP as biomarkers for Alzheimer's disease. Exp Gerontol 45: 23-29.
70. Zlokovic BV. 2008. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5: 409-414.
71. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. 2005. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 15: 78-83.